5-Fluorouracil Is Associated With a Decreased Recurrence Risk in Odontogenic Keratocyst Management: A Retrospective Cohort Study

被引:15
|
作者
Caminiti, Marco F. [1 ]
El-Rabbany, Mohamed [1 ]
Jeon, Justin [2 ]
Bradley, Grace [3 ]
机构
[1] Univ Toronto, Oral & Maxillofacial Surg, Toronto, ON, Canada
[2] Univ Toronto, Fac Dent, Toronto, ON, Canada
[3] Univ Toronto, Oral Pathol, Toronto, ON, Canada
关键词
FLUOROURACIL; TOXICITY; TUMOR;
D O I
10.1016/j.joms.2020.07.215
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose: The antimetabolite drug, 5-fluorouracil (5-FU), has been suggested as an adjunctive treatment to reduce the recurrence rates of odontogenic keratocysts (OKCs). We report on the use of 5-FU in the management of patients with OKCs as a postenucleation intracavity topical dressing. Methods: For this retrospective cohort study, we collected all data of sequentially treated cases presenting to the University of Toronto's hospital clinics for the management of biopsy-proven OKCs. Chart reviews were conducted to identify all patients treated with 5-FU cream, and compare them to patients treated with modified Carnoy's solution (MCS). In the treatment group, all patients were treated in an identical manner with enucleation and peripheral ostectomy followed by the application of 5% 5-FU cream for 24 hours. Preoperative and postoperative radiographs were collected to determine the time to recurrence of the disease, and the techniques were compared via a multivariate Cox regression analysis. Results: Seventy patients were found to be eligible for inclusion in this study. Of these, 34 patients were treated with 5% topical 5-FU, and 36 patients were managed with MCS. The median follow-up time in the 5-FU group was 22 months (interquartile range, 36), compared with 27 months (interquartile range, 37) for the MCS group (P = .40). No recurrences were identified in the 5-FU group, compared with 9 recurrences (25%) in patients treated with MCS. 5-FU was shown to be significantly negatively associated with time to disease resolution (P < .01). Conclusions: Results from this study suggest that when used topically, 5-FU effectively lowers the recurrence rates of OKCs. Further large scale, case-controlled studies are being investigated at our center and are warranted to make definitive conclusions regarding the effectiveness of this novel technique when compared with conventional therapies. (C) 2020 American Association of Oral and Maxillofacial Surgeons
引用
收藏
页码:814 / 821
页数:8
相关论文
共 50 条
  • [31] Intralesional 5-fluorouracil as a management for cutaneous squamous cell carcinomas: A rural Australian retrospective case series
    Luu, William
    Mcrae, Michelle Yvonne
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (04) : 556 - 559
  • [32] Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: A retrospective study
    Tahara M.
    Ohtsu A.
    Boku N.
    Nagashima F.
    Muto M.
    Sano Y.
    Yoshida M.
    Mera K.
    Hironaka S.-I.
    Tajiri H.
    Yoshida S.
    Gastric Cancer, 2001, 4 (4) : 212 - 218
  • [33] The Efficacy of 5-Fluorouracil Bleb Needling Performed 1 Year or More Posttrabeculectomy A Retrospective Study
    Kapasi, Mustafa S.
    Birt, Catherine M.
    JOURNAL OF GLAUCOMA, 2009, 18 (02) : 144 - 148
  • [34] Retrospective study of the safety of administering pegfilgrastim on the same day of 5-Fluorouracil pump disconnect.
    Patel, Nikita
    Wu, Christina
    Draper, Amber
    LaFollette, Jennifer Ann
    Brutcher, Edith
    El-Rayes, Bassel F.
    Alese, Olatunji B.
    Shaib, Walid Labib
    Akce, Mehmet
    Chen, Zhengjia
    Kim, Chaejin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Intralesional 5-Fluorouracil for the Nonsurgical Management of Low-Risk, Invasive Squamous Cell Carcinoma
    Dando, Emily E.
    Lim, Geoffrey F. S.
    Lim, Scott J. M.
    Kim, ChangHyun
    Pugliano-Mauro, Melissa
    DERMATOLOGIC SURGERY, 2020, 46 (01) : 126 - 130
  • [36] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [37] Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study
    Vazquez, Carolina
    Orlova, Maria
    Angriman, Federico
    Minatta, Jose N.
    Scibona, Paula
    Verzura, Maria A.
    Jauregui, Esteban G.
    Diaz de Arce, Heidy
    Pallotta, Maria G.
    Belloso, Waldo H.
    ANTI-CANCER DRUGS, 2017, 28 (09) : 1039 - 1046
  • [38] Utility of Thymidylate Synthase Genotyping for 5-Fluorouracil Chemotherapy in a Large,Colorectal Cancer Cohort Study
    Elsberry, D.
    Welker, N. C.
    Cho, M.
    Kim, I.
    Wilson, A. R.
    Bronner, M. P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 915 - 916
  • [39] Risk Factors Associated With Postoperative Recurrence in Patients With Tenosynovial Giant Cell Tumor of the Hand A Retrospective Cohort Study
    Shi, Jialu
    Zheng, Jingwei
    Zhou, Xijie
    Li, Zhijie
    Chen, Xinglong
    Gao, Weiyang
    Yan, Hede
    ANNALS OF PLASTIC SURGERY, 2019, 83 (05) : 523 - 528
  • [40] A retrospective study on the management of massive hemoptysis by bronchial artery embolization: risk factors associated with recurrence of hemoptysis
    Li, Hui
    Ding, Xu
    Zhai, Shuo
    Gao, Kun
    BMC PULMONARY MEDICINE, 2023, 23 (01)